Latest Rheumatology Articles

• Upadacitinib — An Up-and-Comer for Treatment of Giant-Cell Arteritis May 29, 2025
  Ever since the early use of cortisone for giant-cell arteritis in the 1950s,1 glucocorticoids have been a foundational treatment for this form of large-vessel vasculitis, providing clinical benefit and reducing the risk of blindness. Indeed, for almost seven decades, the treatment of giant-cell arteritis had been limited largely...
  Matthew J. Koster, Kenneth J. Warrington
• A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis May 29, 2025
  In this randomized, placebo-controlled trial involving patients with giant-cell arteritis, the oral Janus kinase inhibitor upadacitinib (15 mg) significantly improved remission of disease, with less glucocorticoid use.
  Daniel Blockmans, Sara K. Penn, Arathi R. Setty, Wolfgang A. Schmidt, Andrea Rubbert-Roth, Ellen M. Hauge, Helen I. Keen, Tomonori Ishii, Nader Khalidi, Christian Dejaco, Maria C. Cid, Bernhard Hellmich, Meng Liu, Weihan Zhao, Ivan Lagunes, Ana B. Romero, Peter K. Wung, Peter A. Merkel, the SELECT-GCA Study Group*
• Progress through Persistence — Turning the Page in Pulmonary Fibrosis Clinical Trials May 19, 2025
  The field of pulmonary fibrosis has come a long way in the past 25 years, with the approach to patient care evolving from a predominantly experience-based decision-making model to a more data-driven model. Along that journey, we have learned that certain practices that were considered to be standards of care...
  Joyce S. Lee